TriangleNALIRIFOX (NCT05851924)
NALIRIFOX trial for Pancreatic Ductal Adenocarcinoma (NCT05851924). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, borderline-resectable or locally advanced pancreatic ductal adenocarcinoma, without distant spread.
The idea: give four months of NALIRIFOX—liposomal irinotecan, oxaliplatin, leucovorin and fluorouracil—then, if cancer has not progressed, radiation with oral capecitabine. Capecitabine becomes fluorouracil, which interferes with DNA production. Surgery follows only when reassessment shows it is feasible. Researchers track progression, recurrence, survival and quality of life.
This phase 2 study plans 60 patients. MSK’s Alice Wei leads it in New York; seven US sites are listed, six with limited activities.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.